Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting

NEXT STORY
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
PREV STORY
Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study

author_avatar
NASDAQ Market News

REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or ...

author_avatar
NASDAQ Market News

Global Tissue Imaging Market (2020 to 2030) – Focus on Technology, Product, Application, End-user, 14 Countries Data and Competitive Landscape

author_avatar
NASDAQ Market News